The metallo-␤-lactamase GIM-1 (German imipenemase) has been found so far only in clinical isolates of Pseudomonas aeruginosa from Germany. Here we report the detection of bla GIM-1 in a clinical strain of Serratia marcescens that was isolated from urine, blood, and wound samples over a period of 20 months. The strain was repeatedly isolated from one patient in two German hospitals and an outpatient department located in the region in which all previously described GIM-1-producing P. aeruginosa strains were identified.
bioMérieux, Nuertingen, Germany) showed ambiguous results and could not clearly confirm the presence of a carbapenem-hydrolyzing enzyme. During an occurrence of S. marcescens strain MG2504 in 2009, we recovered 1,024 further nonduplicate S. marcescens isolates from different hospitals and outpatient departments in North Rhine-Westphalia. Altogether, 20 isolates (2.0%) were resistant to expanded-spectrum cephalosporins (ceftazidime, cefotaxime). In 2010, we recovered 998 isolates, with 59 (6%) isolates being resistant to ceftazidime and/or cefotaxime, and in 2011, the resistance rate increased to 10% (102 of 1,047 isolates). However, S. marcescens MG2504, isolated in 2009 and 2010, was the only strain exhibiting reduced susceptibility to carbapenems. Molecular screening by PCR and sequencing was performed for different extended-spectrum ␤-lactamase (ESBL) genes (bla TEM , bla SHV , bla CTX-M , and bla BES ) and carbapenemase genes (bla , bla SME ,bla GES , and bla KPC ) as well as for the most-commonly detected metallo-␤-lactamase (MBL) genes (bla IMP , bla VIM , and bla NDM ) and for locally occurring types (bla GIM , bla SPM , and bla SIM ) as described previously (2, 6, 9, 13, 14, 18) . Using PCR and sequence analysis, we identified the MBL gene bla GIM-1 in S. marcescens MG2504. Detailed investigation of the bla GIM-1 genetic environment by PCR mapping (primer walking [4] ) showed an integron structure comparable to structures that have been identified in bla GIM -harboring Pseudomonas aeruginosa isolates collected in 2002 and 2009 to 2010 in North Rhine-Westphalia, Germany (4, 20) . In contrast to these P. aeruginosa integron structures, in S. marcescens, the aadA1 gene was not interrupted by a copy of the insertion sequence IS1394 (Fig. 1A and B) .
S. marcescens isolates producing MBLs of the VIM and IMP types have been reported from South Korea, Japan, Taiwan, and Australia (10, 22, 12, 16) . The GIM-1 enzyme that we found in S. marcescens MG2504 was described so far in only six clinical P. aeruginosa strains from a localized region in Germany (4, 20) . Interestingly, in two hospitals in which the patient was treated, we identified two different multidrug-resistant P. aeruginosa strains harboring bla GIM-1 . One P. aeruginosa strain was isolated 4 months before the first detection of the S. marcescens strain in another ward from a patient with colonization. The second P. aeruginosa isolate was recovered from lower-respiratory-tract specimens 9 months after detection of the S. marcescens strain in the same ward, isolated from a patient with pneumonia. However, in both P. aeruginosa isolates, bla GIM-1 was located within integron structures widely different from those of S. marcescens (Fig. 1C  and D) .
Transferability of the bla GIM-1 gene was tested by broth mating assays using sodium azide-resistant Escherichia coli K12J53 as the recipient. Selection of transconjugants was performed on Mueller-Hinton agar plates that contained sodium azide (200 mg/liter) and ampicillin (100 mg/liter) or meropenem (0.5 mg/liter). For determination of plasmid size, whole genomic DNA was digested with S1 nuclease and subjected to pulsed-field gel electrophoresis (PFGE) as described previously (1) . Southern hybridization using digoxigenin-dUTP-labeled probes and signal detection using CDP-Star were performed following the manufacturer's guidelines (Roche Diagnostics Ltd., West Sussex, United Kingdom). The broth mate conjugation experiment in the present study was not successful, but we detected bla GIM-1 on a plasmid with a size of ca. 22 kb in the clinical S. marcescens MG2504 strain. Replicon typing for identification of the plasmid was performed as described previously (3). However, a replicon type could not be determined.
In the first GIM-1-positive P. aeruginosa isolate from 2002, bla GIM-1 was found to be located on a 22-kb plasmid (4). We speculate that a bla GIM-1 -carrying plasmid was transferred between species, from P. aeruginosa to S. marcescens. Since the source of the bla GIM-1 gene and the bla GIM-1 -carrying plasmid is still unknown, we assume that the spread in other Gram-negative species is possible and probably ongoing. A problem is the slightly increased MIC values for meropenem and imipenem, leading to ambiguous results of phenotypic carbapenemase tests, which substantially complicates the diagnostics of these strains in common microbiological laboratories without having the possibility of using PCR. Therefore, the prevalence of GIM-1-producing S. marcescens and P. aeruginosa and the presence of other GIM-1-possessing Gram-negative species in Germany are most probably underestimated.
The present multidrug-resistant isolate of S. marcescens (MG2504) contained the MBL gene bla GIM-1 , previously described only in P. aeruginosa. This indicates the potential of transmission of bla GIM-1 -carrying mobile genetic elements or plasmids between different Gram-negative species. Extensive resistance surveillance, including molecular epidemiological investigations, is needed to learn more about the emergence and dissemination of GIM-1-producing bacteria in Germany.
Nucleotide sequence accession number. The nucleotide sequence of the S. marcescens MG2504 integron structure has been registered in the GenBank database under accession number JQ409537.
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